FIELD: biotechnology.
SUBSTANCE: there are presented antibodies and their antigen-binding fragments which specifically bind to proprotein convertase of subtilisin-kexin type 9 (PCSK9), nucleic acids coding them, expression vectors and host cells. There are also presented pharmaceutical compositions, combinations and kits containing the above antibodies. Besides, the invention refers to using the antibodies for treating or preventing a PCSK9-mediated disease or pathological condition.
EFFECT: invention provides the improved function of reducing cholesterol, not related to HDL, in blood plasma.
46 cl, 48 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| HIGH-AFFINITY T-CELL RECEPTOR FOR AFP ANTIGEN RECOGNITION | 2019 |
|
RU2836365C2 |
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| COMPOSITIONS AND METHODS OF ACTIVATING INTEGRINS | 2020 |
|
RU2836262C1 |
